GLP-1 Market
LLY $1149.85 ▼ -0.6% NVO $37.40 ▼ -1.3% PFE $28.12 ▼ -1.4% VKTX $30.51 ▼ -6.4% KLRA $11.03 ▼ -3.4% GPCR $28.98 ▼ -7.3% RHHBY $52.35 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Atezolizumab

Company
National Cancer Institute (NCI)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
98 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

98 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 2, 2026

Find a Clinical Trial Near Me

See recruiting studies for Atezolizumab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02693535

    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    Not yet reported American Society of Clinical Oncology 4200 participants Est. completion 2028-12-31 181 sites
    Other conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT03767075

    A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

    Not yet reported Vall d'Hebron Institute of Oncology 1000 participants Est. completion 2026-11 8 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT04273061

    Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

    Not yet reported British Columbia Cancer Agency 50 participants Est. completion 2027-10 2 sites Stand-alone
    Other conditions: Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
    View official trial listing →
  • Recruiting NCT NCT04302025

    A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    Not yet reported Genentech, Inc. 99 participants Est. completion 2030-05-30 38 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT04341181

    ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

    Not yet reported Ulrik Lassen 300 participants Est. completion 2030-04-30 7 sites Stand-alone
    Other conditions: Cancer, Tumors, Neoplasms, Neoplasia
    View official trial listing →
  • Recruiting NCT NCT04434040

    Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    Not yet reported Dana-Farber Cancer Institute 40 participants Est. completion 2027-12-30 7 sites Stand-alone
    Other conditions: Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
    View official trial listing →
  • Recruiting NCT NCT04467723

    Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

    Not yet reported, Not yet reported University of Kansas Medical Center 25 participants Est. completion 2027-08 2 sites Stand-alone
    Other conditions: NSCLC Stage IV, NSCLC, Recurrent
    View official trial listing →
  • Recruiting NCT NCT04691817

    Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

    Not yet reported, Not yet reported Abramson Cancer Center at Penn Medicine 28 participants Est. completion 2027-09 1 site Stand-alone
    Other conditions: Lung Cancer, Nonsmall Cell
    View official trial listing →
  • Recruiting NCT NCT04696575

    Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

    Not yet reported Roswell Park Cancer Institute 28 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Extensive Stage Lung Small Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT04802759

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 316 participants Est. completion 2029-05-30 32 sites Stand-alone
    Other conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04803994

    The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

    Not yet reported Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 434 participants Est. completion 2027-07 72 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT04812366

    Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

    Not yet reported University of British Columbia 315 participants Est. completion 2027-06-01 9 sites
    Other conditions: Prostate Cancer
    View official trial listing →
  • Recruiting NCT NCT04819243

    PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

    Not yet reported Samsung Medical Center 178 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Premenopausal HR+/HER2- Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04865250

    Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

    Not yet reported University Hospital Heidelberg 20 participants Est. completion 2026-12-30 1 site Stand-alone
    Other conditions: NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB
    View official trial listing →
  • Recruiting NCT NCT04929223

    A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    Not yet reported Hoffmann-La Roche 542 participants Est. completion 2030-08-31 84 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT04954599

    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

    Not yet reported, Not yet reported Maastricht University Medical Center 126 participants Est. completion 2027-05 5 sites
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Recruiting NCT NCT04981509

    Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

    Not yet reported National Cancer Institute (NCI) 65 participants Est. completion 2027-12-31 13 sites Stand-alone
    Other conditions: Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT04996017

    Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

    Not yet reported Gruppo Oncologico Italiano di Ricerca Clinica 162 participants Est. completion 2029-06-30 19 sites Stand-alone
    Other conditions: Mesotheliomas Pleural
    View official trial listing →
  • Recruiting NCT NCT05000294

    Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Not yet reported, Not yet reported University of Florida 29 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
    View official trial listing →
  • Recruiting NCT NCT05152472

    A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

    Not yet reported Centre Leon Berard 110 participants Est. completion 2027-10 13 sites Stand-alone
    Other conditions: Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
    View official trial listing →
  • Recruiting NCT NCT05159245

    The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

    Not yet reported Helsinki University Central Hospital 250 participants Est. completion 2026-11-25 5 sites Stand-alone
    Other conditions: Advanced Cancer, Solid Tumor, Haematological Malignancy
    View official trial listing →
  • Recruiting NCT NCT05168618

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Not yet reported University of Utah 33 participants Est. completion 2027-01 1 site Stand-alone
    Other conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT05263830

    Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

    Assistance Publique - Hôpitaux de Paris 240 participants Est. completion 2029-09-08 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05287464

    International Multicentric Study ARON-1

    Hospital of Macerata 1220 participants Est. completion 2027-09-30 1 site
    Other conditions: Metastatic Renal Cell Carcinoma (mRCC)
    View official trial listing →
  • Recruiting NCT NCT05317858

    Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

    Not yet reported InSightec 30 participants Est. completion 2027-12-01 14 sites Stand-alone
    Other conditions: Brain Tumor, Non Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT05377034

    Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

    Not yet reported National Cancer Centre, Singapore 100 participants Est. completion 2028-01-31 14 sites Stand-alone
    Other conditions: Locally Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05394337

    Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 10 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Metastatic Malignancy
    View official trial listing →
  • Recruiting NCT NCT05423210

    Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

    Not yet reported Stony Brook University 12 participants Est. completion 2029-08 1 site Stand-alone
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Recruiting NCT NCT05501665

    Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

    Not yet reported, Not yet reported Vanderbilt-Ingram Cancer Center 25 participants Est. completion 2027-02-01 1 site Stand-alone
    Other conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT05516628

    Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

    Not yet reported National Cancer Centre, Singapore 30 participants Est. completion 2027-03 6 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05538091

    Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

    Not yet reported Ronald Buckanovich 48 participants Est. completion 2032-09-30 1 site Stand-alone
    Other conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor
    View official trial listing →
  • Recruiting NCT NCT05549297

    Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

    Not yet reported Immunocore Ltd 540 participants Est. completion 2028-07 82 sites
    Other conditions: Advanced Melanoma
    View official trial listing →
  • Recruiting NCT NCT05582499

    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

    Not yet reported Fudan University 716 participants Est. completion 2029-09 1 site
    Other conditions: Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05652686

    A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

    Not yet reported, Not yet reported Phanes Therapeutics 203 participants Est. completion 2028-08 15 sites Stand-alone
    Other conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
    View official trial listing →
  • Recruiting NCT NCT05703971

    Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

    Not yet reported, Not yet reported Genprex, Inc. 62 participants Est. completion 2028-06 17 sites Stand-alone
    Other conditions: Small Cell Lung Cancer Extensive Stage
    View official trial listing →
  • Recruiting NCT NCT05713994

    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

    Ze-yang Ding, MD 300 participants Est. completion 2025-12-30 2 sites
    Other conditions: Hepatocellular Carcinoma Non-resectable
    View official trial listing →
  • Recruiting NCT NCT05751343

    Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial

    Not yet reported Sun Yat-sen University 55 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05763277

    Ate-Bev Early Response Prediction Model in Advanced HCC

    Seoul National University Hospital 170 participants Est. completion 2026-12-31 1 site
    Other conditions: Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation
    View official trial listing →
  • Recruiting NCT NCT05765084

    Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

    Not yet reported, Not yet reported University Hospital, Antwerp 15 participants Est. completion 2027-10 3 sites Stand-alone
    Other conditions: Malignant Pleural Mesothelioma
    View official trial listing →
  • Recruiting NCT NCT05834413

    Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

    Not yet reported Shanghai University of Traditional Chinese Medicine 367 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT05907980

    A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

    Not yet reported Chugai Pharmaceutical 209 participants Est. completion 2027-10-31 14 sites Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05937295

    FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

    Not yet reported University Hospital Tuebingen 20 participants Est. completion 2027-01 1 site Stand-alone
    Other conditions: Fibrolamellar Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05944237

    HTL0039732 in Participants With Advanced Solid Tumours

    Not yet reported, Not yet reported Cancer Research UK 150 participants Est. completion 2028-12-31 6 sites Stand-alone
    Other conditions: Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
    View official trial listing →
  • Recruiting NCT NCT05984511

    TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

    Not yet reported Third Affiliated Hospital, Sun Yat-Sen University 234 participants Est. completion 2029-08-01 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
    View official trial listing →
  • Recruiting NCT NCT06031233

    Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

    Not yet reported Isala 776 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Oncology, Infusion Reaction
    View official trial listing →
  • Recruiting NCT NCT06043674

    Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

    Not yet reported Christine Ryan 70 participants Est. completion 2033-01-15 5 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Richter's Transformation
    View official trial listing →
  • Recruiting NCT NCT06069726

    A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

    Not yet reported Duke University 80 participants Est. completion 2028-01-01 4 sites Stand-alone
    Other conditions: Recurrent Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT06161532

    Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

    Not yet reported National Cancer Institute (NCI) 60 participants Est. completion 2028-11-01 1 site Stand-alone
    Other conditions: Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract, Primary Adenocarcinoma of the Bladder, Primary Adenocarcinoma of the Urinary Tract, Renal Medullary Carcinoma, Squamous Cell Carcinoma of the Penis
    View official trial listing →
  • Recruiting NCT NCT06179069

    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

    Not yet reported Zai Lab (Shanghai) Co., Ltd. 339 participants Est. completion 2027-07-31 38 sites Stand-alone
    Other conditions: SCLC
    View official trial listing →
  • Recruiting NCT NCT06182072

    ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

    Not yet reported ProDa BioTech, LLC 46 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
    View official trial listing →
  • Recruiting NCT NCT06254248

    Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

    Not yet reported Assistance Publique - Hôpitaux de Paris 50 participants Est. completion 2030-01-01 10 sites Stand-alone
    Other conditions: Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
    View official trial listing →
  • Recruiting NCT NCT06254911

    Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

    Not yet reported Emory University 20 participants Est. completion 2026-12-16 1 site Stand-alone
    Other conditions: Oropharynx Cancer, Stage I
    View official trial listing →
  • Recruiting NCT NCT06294548

    A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

    Not yet reported, Not yet reported University of Alabama at Birmingham 45 participants Est. completion 2028-08-28 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06323382

    Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

    Sun Yat-sen University 240 participants Est. completion 2025-12-30 1 site
    Other conditions: Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
    View official trial listing →
  • Recruiting NCT NCT06342037

    NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

    Not yet reported The Netherlands Cancer Institute 60 participants Est. completion 2030-04-01 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06422403

    A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

    Not yet reported National University Hospital, Singapore 360 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06444815

    A Study of VET3-TGI in Patients With Solid Tumors

    Not yet reported KaliVir Immunotherapeutics 60 participants Est. completion 2027-12-31 7 sites Stand-alone
    Obstructive sleep apnea Other conditions: Solid Tumor, Adult, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06463665

    Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

    Not yet reported Genelux Corporation 142 participants Est. completion 2029-07 15 sites Stand-alone
    Other conditions: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
    View official trial listing →
  • Recruiting NCT NCT06478693

    A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

    Not yet reported Myeloid Therapeutics 70 participants Est. completion 2028-05-31 9 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06529081

    Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

    Not yet reported Copernicus Memorial Hospital 165 participants Est. completion 2029-12-31 2 sites
    Other conditions: Small Cell Lung Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06551272

    Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

    Not yet reported Center Eugene Marquis 34 participants Est. completion 2026-12-12 6 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06622486

    First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

    Not yet reported, Not yet reported Egle Therapeutics 50 participants Est. completion 2027-01-23 8 sites
    Other conditions: Solid Tumor, Adult
    View official trial listing →
  • Recruiting NCT NCT06695026

    A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

    Not yet reported, Not yet reported Rznomics, Inc. 45 participants Est. completion 2027-10 9 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT06725121

    Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

    Not yet reported, Not yet reported University Health Network, Toronto 48 participants Est. completion 2034-06 2 sites
    Other conditions: Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
    View official trial listing →
  • Recruiting NCT NCT06731270

    Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

    Not yet reported Emory University 20 participants Est. completion 2028-01-01 2 sites Stand-alone
    Other conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT06733038

    FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

    Not yet reported Gruppo Oncologico del Nord-Ovest 238 participants Est. completion 2029-04-01 24 sites Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT06768307

    Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

    Not yet reported Peking University Cancer Hospital & Institute 60 participants Est. completion 2028-01-31 1 site Stand-alone
    Other conditions: SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy
    View official trial listing →
  • Recruiting NCT NCT06771518

    Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

    Not yet reported Regina Elena Cancer Institute 37 participants Est. completion 2026-12-15 1 site Stand-alone
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06789757

    The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

    Not yet reported Inova Health Care Services 19 participants Est. completion 2028-01-27 2 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06793553

    Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

    Not yet reported Japan Breast Cancer Research Group 106 participants Est. completion 2028-09-30 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06806579

    Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

    IRCCS Azienda Ospedaliero-Universitaria di Bologna 1000 participants Est. completion 2031-10-31 24 sites
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT06819566

    Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC

    Not yet reported Asan Medical Center 44 participants Est. completion 2029-03-31 1 site
    Other conditions: Hepatocellular Carcinoma, Esophageal Varix, Bleeding Esophageal Varices
    View official trial listing →
  • Recruiting NCT NCT06830694

    Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

    Not yet reported Sehhoon Park 50 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: Small Cell Carcinoma of Lung
    View official trial listing →
  • Recruiting NCT NCT06840782

    First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 124 participants Est. completion 2030-02 3 sites Stand-alone
    Other conditions: Oligometastatic Non-small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Recruiting NCT NCT07010497

    A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

    Not yet reported Asan Medical Center 33 participants Est. completion 2029-03-31 3 sites Stand-alone
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Recruiting NCT NCT07011004

    A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

    Not yet reported Memorial Sloan Kettering Cancer Center 18 participants Est. completion 2028-05 7 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
    View official trial listing →
  • Recruiting NCT NCT07049848

    SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2030-01-01 1 site Stand-alone
    Other conditions: Soft Tissue Sarcoma
    View official trial listing →
  • Recruiting NCT NCT07091942

    Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

    National Taiwan University Hospital 1600 participants Est. completion 2026-06-30 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07155174

    A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

    Not yet reported AbbVie 180 participants Est. completion 2031-09 68 sites Stand-alone
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07157969

    ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

    Not yet reported Peking Union Medical College Hospital 300 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: HCC - Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07195695

    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    Not yet reported Boehringer Ingelheim 400 participants Est. completion 2036-09-02 202 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07227597

    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 170 participants Est. completion 2030-12-30 54 sites Stand-alone
    Other conditions: Small Cell Lung Cancer Extensive Stage
    View official trial listing →
  • Recruiting NCT NCT07239245

    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30 participants Est. completion 2030-11-10 4 sites Stand-alone
    Other conditions: Resectable Hepatocellular Carcinoma With High Risk of Recurrence
    View official trial listing →
  • Recruiting NCT NCT07246668

    A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

    Not yet reported Yonsei University 52 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma, Liver Neoplasms, Carcinoma, Hepatocellular
    View official trial listing →
  • Recruiting NCT NCT07263438

    Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

    Not yet reported Centre Hospitalier Universitaire Vaudois 59 participants Est. completion 2030-12-31 7 sites Stand-alone
    Other conditions: Glioblastoma, Recurrence Tumor
    View official trial listing →
  • Recruiting NCT NCT07276100

    Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

    Not yet reported IRCCS Azienda Ospedaliero-Universitaria di Bologna 15 participants Est. completion 2029-01-01 1 site Stand-alone
    Other conditions: Hepato Cellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT07284121

    A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

    Hoffmann-La Roche 700 participants Est. completion 2028-12-31 92 sites
    Other conditions: Lung Cancer, Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07285850

    The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

    Not yet reported, Not yet reported Eastern Hepatobiliary Surgery Hospital 20 participants Est. completion 2026-08-30 1 site Stand-alone
    Other conditions: HCC - Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07293468

    Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

    Not yet reported, Not yet reported Tuen Mun Hospital 106 participants Est. completion 2034-12-31 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT07317414

    β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

    Not yet reported Peking Union Medical College Hospital 158 participants Est. completion 2030-12-05 3 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07322341

    SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

    Not yet reported University of Washington 32 participants Est. completion 2031-11-01 1 site Stand-alone
    Other conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Recruiting NCT NCT07365930

    NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

    Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 350 participants Est. completion 2031-12-17 1 site
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT07538128

    Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

    Not yet reported Huashan Hospital 10 participants Est. completion 2027-02-28 1 site Stand-alone
    Other conditions: Recurrent Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT07545954

    DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

    Not yet reported Washington University School of Medicine 20 participants Est. completion 2030-02-28 1 site Stand-alone
    Other conditions: Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
    View official trial listing →
  • Recruiting NCT NCT07610551

    Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma

    Air Force Military Medical University, China 50 participants Est. completion 2026-12-31 1 site
    Other conditions: HCC - Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07625644

    BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

    Not yet reported SystImmune Inc. 550 participants Est. completion 2031-06 62 sites Stand-alone
    Other conditions: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
    View official trial listing →
  • Recruiting NCT NCT07759856

    NK Cells Plus ICI for SCLC Maintenance

    Not yet reported Tianjin First Central Hospital 42 participants Est. completion 2029-08 1 site Stand-alone
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07793695

    Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma

    Not yet reported Anhui Provincial Hospital 60 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT00729664

    Multiple Ascending Dose (MDX1105-01)

    Not yet reported Bristol-Myers Squibb 281 participants Est. completion 2015-07 11 sites
    Other conditions: Cancer, Multiple Indications
    View official trial listing →
  • Completed NCT NCT01375842

    A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

    Not yet reported Genentech, Inc. 661 participants Est. completion 2018-09-30 21 sites Stand-alone
    Other conditions: Tumors, Hematologic Malignancies
    View official trial listing →
  • Completed NCT NCT01633970

    A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

    Not yet reported Genentech, Inc. 240 participants Est. completion 2020-02-26 11 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT01656642

    A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

    Not yet reported Genentech, Inc. 67 participants Est. completion 2020-03-25 8 sites Stand-alone
    Other conditions: Malignant Melanoma
    View official trial listing →
  • Suspended NCT NCT01810913

    Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 613 participants Est. completion 2027-01-01 342 sites Stand-alone
    Other conditions: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
    View official trial listing →
  • Active, not recruiting NCT NCT01898117

    Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

    Not yet reported The Netherlands Cancer Institute 304 participants Est. completion 2030-12 49 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02013219

    A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported Hoffmann-La Roche 52 participants Est. completion 2020-02-05 17 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02091141

    My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

    Not yet reported Genentech, Inc. 673 participants Est. completion 2023-05-24 60 sites Stand-alone
    Other conditions: Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
    View official trial listing →
  • Completed NCT NCT02304393

    A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

    Not yet reported Hoffmann-La Roche 140 participants Est. completion 2019-11-07 11 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT02314481

    Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

    Not yet reported University College, London 50 participants Est. completion 2025-11-30 1 site
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02323191

    A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

    Not yet reported Hoffmann-La Roche 221 participants Est. completion 2020-08-21 12 sites Stand-alone
    Other conditions: Solid Cancers
    View official trial listing →
  • Completed NCT NCT02350673

    A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

    Not yet reported Hoffmann-La Roche 70 participants Est. completion 2019-12-16 14 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT02367781

    A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported Hoffmann-La Roche 723 participants Est. completion 2021-01-18 132 sites Stand-alone
    Other conditions: Carcinoma, Non-Squamous Non-Small Cell Lung
    View official trial listing →
  • Completed NCT NCT02367794

    A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

    Not yet reported Hoffmann-La Roche 1021 participants Est. completion 2021-02-17 242 sites Stand-alone
    Other conditions: Squamous Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT02400814

    MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

    Not yet reported Megan Daly, MD 27 participants Est. completion 2021-09-29 1 site
    Other conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02409342

    A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

    Not yet reported Hoffmann-La Roche 572 participants Est. completion 2022-03-08 142 sites Stand-alone
    Other conditions: Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT02450331

    A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

    Not yet reported Hoffmann-La Roche 809 participants Est. completion 2022-06-14 186 sites Stand-alone
    Other conditions: Carcinoma, Transitional Cell
    View official trial listing →
  • Completed NCT NCT02451423

    Neoadjuvant Atezolizumab in Localized Bladder Cancer

    Not yet reported Lawrence Fong 23 participants Est. completion 2023-03-31 1 site Stand-alone
    Other conditions: Carcinoma, Transitional Cell
    View official trial listing →
  • Completed NCT NCT02458638

    A Study of Atezolizumab in Advanced Solid Tumors

    Not yet reported Hoffmann-La Roche 474 participants Est. completion 2020-07-28 48 sites Stand-alone
    Other conditions: Tumors
    View official trial listing →
  • Completed NCT NCT02463994

    A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

    Not yet reported University of Michigan Rogel Cancer Center 12 participants Est. completion 2018-11-07 2 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT02478099

    MPDL3280A-treatment-IST-UMCG

    Not yet reported University Medical Center Groningen 81 participants Est. completion 2024-07 1 site
    Other conditions: Locally Advanced or Metastatic Solid Tumors
    View official trial listing →
  • Withdrawn NCT NCT02495636

    Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

    Not yet reported Yale University Est. completion 2017-07 1 site
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02500407

    A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported Genentech, Inc. 713 participants Est. completion 2025-09-01 35 sites Stand-alone
    Other conditions: Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
    View official trial listing →
  • Completed NCT NCT02508870

    A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

    Not yet reported Hoffmann-La Roche 46 participants Est. completion 2019-06-10 15 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT02530489

    Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 37 participants Est. completion 2025-05-23 1 site Stand-alone
    Other conditions: Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
    View official trial listing →
  • Terminated NCT NCT02541604

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

    Not yet reported, Not yet reported Hoffmann-La Roche 87 participants Est. completion 2019-06-06 30 sites Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Terminated NCT NCT02543645

    A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

    Not yet reported Celldex Therapeutics 18 participants Est. completion 2017-05-22 4 sites Stand-alone
    Other conditions: Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02594384

    A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

    Not yet reported OrphAI Therapeutics 62 participants Est. completion 2023-03-30 11 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
    View official trial listing →
  • Completed NCT NCT02599454

    Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

    Not yet reported Megan Daly, MD 20 participants Est. completion 2024-02-20 2 sites Stand-alone
    Other conditions: Stage I Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT02630186

    A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

    Not yet reported, Not yet reported Clovis Oncology, Inc. 3 participants Est. completion 2017-09-05 1 site
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02650713

    A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

    Not yet reported Hoffmann-La Roche 228 participants Est. completion 2020-01-13 24 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT02655822

    Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

    Not yet reported Corvus Pharmaceuticals, Inc. 502 participants Est. completion 2021-07 20 sites Stand-alone
    Other conditions: Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
    View official trial listing →
  • Completed NCT NCT02657434

    A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

    Not yet reported Hoffmann-La Roche 578 participants Est. completion 2022-12-13 183 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02659384

    Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 122 participants Est. completion 2022-03 12 sites Stand-alone
    Other conditions: Ovarian Neoplasms
    View official trial listing →
  • Completed NCT NCT02662309

    Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

    Not yet reported Queen Mary University of London 96 participants Est. completion 2020-06-11 20 sites
    Other conditions: Bladder Cancer
    View official trial listing →
  • Completed NCT NCT02705196

    LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

    Not yet reported, Not yet reported Lokon Pharma AB 51 participants Est. completion 2025-11-15 2 sites Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT02715531

    A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

    Not yet reported Hoffmann-La Roche 243 participants Est. completion 2021-05-31 30 sites Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Completed NCT NCT02724878

    Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

    Not yet reported Dana-Farber Cancer Institute 65 participants Est. completion 2024-12-31 4 sites Stand-alone
    Other conditions: Advanced Non-Clear Cell Kidney Cancer
    View official trial listing →
  • Completed NCT NCT02729896

    A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Hoffmann-La Roche 36 participants Est. completion 2019-10-07 19 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT02763579

    A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

    Not yet reported Hoffmann-La Roche 503 participants Est. completion 2022-07-07 114 sites Stand-alone
    Other conditions: Small Cell Lung Carcinoma
    View official trial listing →
  • Completed NCT NCT02777710

    Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

    Not yet reported Centre Leon Berard 48 participants Est. completion 2019-12 2 sites
    Other conditions: Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer, Advanced Cancer
    View official trial listing →
  • Completed NCT NCT02788279

    A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

    Not yet reported Hoffmann-La Roche 363 participants Est. completion 2018-12-26 73 sites Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT02794571

    Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

    Not yet reported Genentech, Inc. 518 participants Est. completion 2024-11-13 28 sites Stand-alone
    Other conditions: Advanced/Metastatic Tumors
    View official trial listing →
  • Completed NCT NCT02807636

    Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Not yet reported Hoffmann-La Roche 1213 participants Est. completion 2024-02-12 204 sites Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT02814669

    Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

    Not yet reported Hoffmann-La Roche 45 participants Est. completion 2019-07-31 17 sites Stand-alone
    Other conditions: Castrate-Resistant Prostate Cancer
    View official trial listing →
  • Completed NCT NCT02825940

    A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors

    Not yet reported Hoffmann-La Roche 120 participants Est. completion 2022-11-04 7 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT02844816

    Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

    Not yet reported National Cancer Institute (NCI) 172 participants Est. completion 2024-06-26 272 sites Stand-alone
    Other conditions: Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
    View official trial listing →
  • Active, not recruiting NCT NCT02846623

    Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2027-02-28 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02849496

    Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

    Not yet reported National Cancer Institute (NCI) 89 participants Est. completion 2027-08-26 58 sites Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT02862275

    Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

    Not yet reported National Cancer Institute (NCI) 40 participants Est. completion 2026-11-21 9 sites Stand-alone
    Other conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT02876224

    Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

    Not yet reported Hoffmann-La Roche 51 participants Est. completion 2019-06-25 6 sites Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02883062

    Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

    Not yet reported National Cancer Institute (NCI) 67 participants Est. completion 2027-09-30 14 sites Stand-alone
    Other conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
    View official trial listing →
  • Terminated NCT NCT02890368

    Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

    Not yet reported Pfizer 56 participants Est. completion 2020-03-31 7 sites Stand-alone
    Other conditions: Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
    View official trial listing →
  • Completed NCT NCT02891824

    ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

    Not yet reported ARCAGY/ GINECO GROUP 614 participants Est. completion 2024-02-22 75 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT02892318

    A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

    Not yet reported Hoffmann-La Roche 40 participants Est. completion 2019-12-12 8 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02902029

    Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

    Not yet reported University Hospital, Essen 186 participants Est. completion 2024-03 27 sites Stand-alone
    Other conditions: Malignant Melanoma
    View official trial listing →
  • Completed NCT NCT02908672

    A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

    Not yet reported Hoffmann-La Roche 514 participants Est. completion 2024-07-01 110 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT02912559

    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

    Not yet reported National Cancer Institute (NCI) 712 participants Est. completion 2026-12-18 1049 sites Stand-alone
    Other conditions: Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT02921269

    Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

    Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2021-01-13 22 sites Stand-alone
    Other conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT02926833

    Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Kite, A Gilead Company 37 participants Est. completion 2023-01-12 5 sites Stand-alone
    Other conditions: Refractory Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02928406

    A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

    Not yet reported Hoffmann-La Roche 1004 participants Est. completion 2022-12-12 175 sites Stand-alone
    Other conditions: Urinary Tract Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02935361

    Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

    Not yet reported, Not yet reported University of Southern California 33 participants Est. completion 2027-12-31 5 sites Stand-alone
    Other conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
    View official trial listing →
  • Completed NCT NCT02951767

    A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

    Not yet reported Hoffmann-La Roche 119 participants Est. completion 2023-02-28 77 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Completed NCT NCT02994576

    Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 60 participants Est. completion 2023-03 3 sites Stand-alone
    Other conditions: Nonsmall Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03014648

    Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

    Not yet reported Liza Villaruz, MD 28 participants Est. completion 2022-03-31 2 sites Stand-alone
    Other conditions: Advanced Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03023423

    A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Janssen Research & Development, LLC 100 participants Est. completion 2019-09-26 47 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Terminated NCT NCT03024437

    Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

    Not yet reported, Not yet reported Roberto Pili 31 participants Est. completion 2024-06-24 4 sites Stand-alone
    Other conditions: Metastatic Cancer, Renal Cancer
    View official trial listing →
  • Terminated NCT NCT03029832

    A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

    Not yet reported Genentech, Inc. 5 participants Est. completion 2018-04-25 22 sites Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT03035890

    Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

    Not yet reported West Virginia University 35 participants Est. completion 2022-06-30 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer Metastatic
    View official trial listing →
  • Terminated NCT NCT03050060

    Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

    Not yet reported University of Washington 21 participants Est. completion 2020-07-12 1 site Stand-alone
    Other conditions: Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
    View official trial listing →
  • Terminated NCT NCT03050814

    Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

    Not yet reported National Cancer Institute (NCI) 30 participants Est. completion 2021-08-25 2 sites
    Other conditions: Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT03056599

    Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

    Not yet reported Presage Biosciences 23 participants Est. completion 2021-09-22 3 sites
    Other conditions: Soft Tissue Sarcoma Adult
    View official trial listing →
  • Completed NCT NCT03063762

    Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

    Not yet reported Hoffmann-La Roche 69 participants Est. completion 2021-06-14 23 sites Stand-alone
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT03087864

    PDL-1 Targeting in Resectable Oesophageal Cancer

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 40 participants Est. completion 2019-07-01 1 site Stand-alone
    Other conditions: Esophageal Cancer, Stage II, Esophageal Cancer Stage III
    View official trial listing →
  • Completed NCT NCT03093922

    A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 32 participants Est. completion 2026-09-22 9 sites Stand-alone
    Other conditions: Urothelial Carcinoma, Locally Advanced, Unresectable
    View official trial listing →
  • Completed NCT NCT03102242

    Atezolizumab Immunotherapy in Patients With Advanced NSCLC

    Not yet reported Alliance Foundation Trials, LLC. 64 participants Est. completion 2022-10-01 13 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Terminated NCT NCT03115801

    A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

    Not yet reported Weill Medical College of Cornell University 6 participants Est. completion 2020-10-13 1 site
    Other conditions: Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
    View official trial listing →
  • Terminated NCT NCT03120676

    Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 3 participants Est. completion 2018-11-12 6 sites Stand-alone
    Other conditions: Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03125928

    Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

    Not yet reported Fox Chase Cancer Center 16 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: HER2-positive Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03138889

    Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

    Not yet reported, Not yet reported Nektar Therapeutics 162 participants Est. completion 2022-08-24 38 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT03147040

    AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

    Not yet reported The Netherlands Cancer Institute 23 participants Est. completion 2022-07-01 4 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03148418

    A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

    Not yet reported Hoffmann-La Roche 382 participants Est. completion 2026-12-31 170 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Terminated NCT NCT03154827

    Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

    Not yet reported, Not yet reported BioLineRx, Ltd. 1 participants Est. completion 2020-04-01 12 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03158389

    NCT Neuro Master Match - N²M² (NOA-20)

    Not yet reported, Not yet reported University Hospital Heidelberg 228 participants Est. completion 2023-02-22 13 sites Stand-alone
    Other conditions: Glioblastoma, Adult
    View official trial listing →
  • Completed NCT NCT03164993

    Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

    Not yet reported Oslo University Hospital 68 participants Est. completion 2023-09-30 5 sites
    Other conditions: Cancer, Breast, Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT03174197

    Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2025-09-17 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Glioblastoma
    View official trial listing →
  • Completed NCT NCT03178851

    Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

    Not yet reported Hoffmann-La Roche 155 participants Est. completion 2020-09-21 43 sites Stand-alone
    Other conditions: Malignant Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT03181100

    Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2027-07-31 1 site Stand-alone
    Other conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma
    View official trial listing →
  • Completed NCT NCT03197935

    A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 333 participants Est. completion 2022-09-28 68 sites Stand-alone
    Other conditions: Triple-negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03199885

    Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 190 participants Est. completion 2025-04-04 673 sites Stand-alone
    Other conditions: Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT03201458

    Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

    Not yet reported National Cancer Institute (NCI) 86 participants Est. completion 2024-02-19 41 sites Stand-alone
    Other conditions: Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
    View official trial listing →
  • Terminated NCT NCT03208712

    Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

    Not yet reported University of Michigan Rogel Cancer Center 1 participants Est. completion 2018-08-02 1 site Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Status unknown NCT NCT03228368

    The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

    First Affiliated Hospital of Zhejiang University 10 participants Est. completion 2018-12-01 1 site
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03228537

    Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

    Not yet reported National Cancer Institute (NCI) 28 participants Est. completion 2026-09-18 174 sites Stand-alone
    Other conditions: Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
    View official trial listing →
  • Active, not recruiting NCT NCT03228667

    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

    Not yet reported ImmunityBio, Inc. 40 participants Est. completion 2030-12-31 35 sites Stand-alone
    Obstructive sleep apnea Other conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Mismatch Repair Deficiency, Colorectal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03237780

    Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

    Not yet reported National Cancer Institute (NCI) 72 participants Est. completion 2027-06-30 21 sites Stand-alone
    Other conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT03256344

    Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

    Not yet reported Amgen 36 participants Est. completion 2021-12-03 17 sites Stand-alone
    Other conditions: Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
    View official trial listing →
  • Status unknown NCT NCT03262454

    Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

    Not yet reported National Cancer Center, Korea 35 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Small Cell Lung Cancer Recurrent
    View official trial listing →
  • Terminated NCT NCT03267940

    Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

    Not yet reported Halozyme Therapeutics 85 participants Est. completion 2019-11-11 36 sites Stand-alone
    Other conditions: Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03271372

    Adjuvant Avelumab in Merkel Cell Cancer

    Not yet reported University of Washington 101 participants Est. completion 2029-02-18 9 sites
    Other conditions: Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
    View official trial listing →
  • Terminated NCT NCT03273153

    A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

    Not yet reported Hoffmann-La Roche 446 participants Est. completion 2021-02-19 121 sites Stand-alone
    Other conditions: Advanced BRAFV600 Wild-type Melanoma
    View official trial listing →
  • Completed NCT NCT03280563

    A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 144 participants Est. completion 2024-09-26 22 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT03281954

    Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

    Not yet reported NSABP Foundation Inc 1550 participants Est. completion 2027-11-30 217 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT03292172

    A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 36 participants Est. completion 2019-02-26 11 sites Stand-alone
    Other conditions: Advanced Ovarian Cancer, Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT03312530

    A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

    Not yet reported, Not yet reported Hoffmann-La Roche 49 participants Est. completion 2021-05-18 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03313804

    Priming Immunotherapy in Advanced Disease With Radiation

    Not yet reported John L. Villano, MD, PhD 76 participants Est. completion 2026-02-16 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
    View official trial listing →
  • Completed NCT NCT03321695

    A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

    Hoffmann-La Roche 44 participants Est. completion 2019-03-02 1 site
    Other conditions: Carcinoma, Non-small-cell Lung
    View official trial listing →
  • Completed NCT NCT03330886

    A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

    Hoffmann-La Roche 13 participants Est. completion 2019-03-02 1 site
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Terminated NCT NCT03337698

    A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    Not yet reported, Not yet reported Hoffmann-La Roche 314 participants Est. completion 2025-11-25 29 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Status unknown NCT NCT03340376

    Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

    Not yet reported Universitaire Ziekenhuizen KU Leuven 48 participants Est. completion 2025-09 1 site Stand-alone
    Other conditions: Cervical Cancer
    View official trial listing →
  • Completed NCT NCT03353831

    Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

    Not yet reported AGO Research GmbH 574 participants Est. completion 2025-03-11 111 sites Stand-alone
    Other conditions: Recurrent Ovarian Carcinoma
    View official trial listing →
  • Terminated NCT NCT03357224

    PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 26 participants Est. completion 2022-08-18 2 sites Stand-alone
    Other conditions: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
    View official trial listing →
  • Completed NCT NCT03359239

    Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

    Not yet reported Matthew Galsky 10 participants Est. completion 2021-10-12 1 site Stand-alone
    Other conditions: Urothelial/Bladder Cancer, Nos
    View official trial listing →
  • Withdrawn NCT NCT03369964

    A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Not yet reported Hoffmann-La Roche Est. completion 2019-08-31 2 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Status unknown NCT NCT03371992

    Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC

    Not yet reported Nilogen Oncosystems 25 participants Est. completion 2021-06 1 site
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT03386721

    Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

    Not yet reported Hoffmann-La Roche 256 participants Est. completion 2021-12-30 44 sites Stand-alone
    Other conditions: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
    View official trial listing →
  • Completed NCT NCT03387540

    Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

    Groupe Hospitalier Pitie-Salpetriere 104 participants Est. completion 2017-12-31 1 site
    Other conditions: Myocarditis, Cardiac Complication
    View official trial listing →
  • Completed NCT NCT03394885

    Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

    Not yet reported, Not yet reported Duke University 18 participants Est. completion 2020-07-20 3 sites Stand-alone
    Other conditions: Ovarian Cancer, Ovarian Neoplasms
    View official trial listing →
  • Status unknown NCT NCT03399071

    Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer

    Not yet reported Royal Marsden NHS Foundation Trust 44 participants Est. completion 2025-08-15 1 site
    Other conditions: Gastric Adenocarcinoma, Oesophageal Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03409016

    Biomarkers of Immune-Related Toxicity

    University of Colorado, Denver 69 participants Est. completion 2026-10-17 1 site
    Other conditions: Cancer, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT03417544

    Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

    Not yet reported Nancy Lin, MD 19 participants Est. completion 2026-04-17 2 sites Stand-alone
    Other conditions: HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
    View official trial listing →
  • Terminated NCT NCT03422523

    Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

    Not yet reported University Hospital Southampton NHS Foundation Trust 53 participants Est. completion 2021-11-18 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03436563

    M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2023-08-08 1 site
    Obstructive sleep apnea Other conditions: Colon Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT03438318

    Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

    Not yet reported Regeneron Pharmaceuticals 29 participants Est. completion 2019-12-11 5 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03448835

    Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

    Not yet reported The Netherlands Cancer Institute 20 participants Est. completion 2026-10-31 2 sites Stand-alone
    Other conditions: Stomach Cancer, Gastro Esophageal Junction Cancer
    View official trial listing →
  • Terminated NCT NCT03455556

    Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

    Not yet reported Mayo Clinic 1 participants Est. completion 2020-01-07 3 sites Stand-alone
    Other conditions: Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT03456063

    A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

    Not yet reported Hoffmann-La Roche 453 participants Est. completion 2025-12-31 122 sites Stand-alone
    Other conditions: Non-Small-Cell Lung
    View official trial listing →
  • Terminated NCT NCT03465891

    Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 2 participants Est. completion 2019-12-17 6 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03474094

    Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

    Not yet reported Centre Leon Berard 62 participants Est. completion 2026-12-30 6 sites Stand-alone
    Other conditions: Sarcoma,Soft Tissue
    View official trial listing →
  • Completed NCT NCT03483012

    Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

    Not yet reported Dana-Farber Cancer Institute 6 participants Est. completion 2025-11-12 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03492242

    Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction

    Groupe Hospitalier Pitie-Salpetriere 1000 participants Est. completion 2018-09-30 1 site
    Other conditions: Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases, Autoimmune Diseases, Ophthalmopathy, Myositis, Neuropathy
    View official trial listing →
  • Completed NCT NCT03502785

    INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

    Not yet reported, Not yet reported Inovio Pharmaceuticals 35 participants Est. completion 2025-05-09 11 sites Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Terminated NCT NCT03520686

    Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

    Not yet reported ImmunityBio, Inc. 102 participants Est. completion 2025-10-13 31 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03524170

    Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 24 participants Est. completion 2022-02-10 1 site
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT03526432

    Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

    Not yet reported University of Oklahoma 110 participants Est. completion 2026-09 3 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03533283

    An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Hoffmann-La Roche 211 participants Est. completion 2026-10-16 19 sites Stand-alone
    Other conditions: Non-Hodgkins Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03544723

    Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

    Not yet reported MultiVir, Inc. 40 participants Est. completion 2022-12-31 3 sites
    Other conditions: Solid Tumor, Lymphoma
    View official trial listing →
  • Completed NCT NCT03554083

    Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

    Not yet reported Mayo Clinic 64 participants Est. completion 2025-04-30 3 sites Stand-alone
    Other conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
    View official trial listing →
  • Completed NCT NCT03568656

    Study to Evaluate CCS1477 in Advanced Tumours

    Not yet reported, Not yet reported CellCentric Ltd. 219 participants Est. completion 2025-07-06 19 sites Stand-alone
    Other conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
    View official trial listing →
  • Terminated NCT NCT03579472

    M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 38 participants Est. completion 2022-09-21 2 sites
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT03603184

    Atezolizumab Trial in Endometrial Cancer - AtTEnd

    Not yet reported Mario Negri Institute for Pharmacological Research 549 participants Est. completion 2025-01-20 93 sites Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03614949

    SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 21 participants Est. completion 2028-10 2 sites Stand-alone
    Other conditions: Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
    View official trial listing →
  • Status unknown NCT NCT03616691

    Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC

    Not yet reported Samsung Medical Center 46 participants Est. completion 2020-06-30 Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03620201

    M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 20 participants Est. completion 2024-10-18 1 site
    Other conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT03625141

    A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

    Not yet reported Hoffmann-La Roche 80 participants Est. completion 2023-04-13 22 sites Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Completed NCT NCT03628716

    CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

    Not yet reported Bavarian Nordic 43 participants Est. completion 2021-02-02 6 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Terminated NCT NCT03644823

    Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC

    Not yet reported Oslo University Hospital 21 participants Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT03647956

    Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

    Not yet reported The University of Hong Kong 40 participants Est. completion 2020-04-03 1 site Stand-alone
    Other conditions: NSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation
    View official trial listing →
  • Withdrawn NCT NCT03693573

    A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

    Not yet reported Hoffmann-La Roche Est. completion 2024-01-31 Stand-alone
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT03698461

    Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

    Not yet reported Asan Medical Center 20 participants Est. completion 2023-10-24 1 site Stand-alone
    Other conditions: Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms
    View official trial listing →
  • Terminated NCT NCT03713944

    Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

    Not yet reported Nasser Hanna 30 participants Est. completion 2021-12-16 7 sites Stand-alone
    Other conditions: NSCLC Stage IV, NSCLC, Recurrent
    View official trial listing →
  • Completed NCT NCT03730012

    A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

    Not yet reported, Not yet reported Astellas Pharma Global Development, Inc. 11 participants Est. completion 2021-06-15 12 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
    View official trial listing →
  • Completed NCT NCT03735121

    A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet reported Hoffmann-La Roche 438 participants Est. completion 2024-11-11 74 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03738228

    Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

    Not yet reported National Cancer Institute (NCI) 40 participants Est. completion 2025-09-12 16 sites Stand-alone
    Other conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT03756298

    Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

    Not yet reported National Cancer Center, Korea 284 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03775265

    Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

    Not yet reported National Cancer Institute (NCI) 475 participants Est. completion 2027-06-01 365 sites Stand-alone
    Other conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
    View official trial listing →
  • Withdrawn NCT NCT03786419

    A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

    Not yet reported Health Pharma Professional Research Est. completion 2020-08 1 site Stand-alone
    Other conditions: Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable
    View official trial listing →
  • Active, not recruiting NCT NCT03786692

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

    Not yet reported Fox Chase Cancer Center 107 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4
    View official trial listing →
  • Completed NCT NCT03790397

    Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

    Fundación GECP 169 participants Est. completion 2020-04-01 31 sites
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03800836

    A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 139 participants Est. completion 2022-03-16 18 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03802604

    Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 28 participants Est. completion 2025-03-18 4 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03811002

    Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

    Not yet reported National Cancer Institute (NCI) 544 participants Est. completion 2029-02-21 542 sites Stand-alone
    Other conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT03818061

    Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

    Not yet reported Centre Leon Berard 33 participants Est. completion 2025-01-15 7 sites Stand-alone
    Other conditions: Head and Neck Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT03818997

    Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC Est. completion 2022-04 Stand-alone
    Other conditions: Esophageal Cancer, Biliary Tract Cancer, GastroEsophageal Cancer, Hepatobiliary Neoplasm
    View official trial listing →
  • Completed NCT NCT03836066

    Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

    Not yet reported Fundación GECP 41 participants Est. completion 2024-10-21 25 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03841110

    FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    Not yet reported Fate Therapeutics 37 participants Est. completion 2022-11-15 4 sites Stand-alone
    Obstructive sleep apnea Other conditions: Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Merkel Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT03850028

    Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

    Not yet reported University Medical Center Groningen Est. completion 2022-05-01 2 sites
    Other conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    View official trial listing →
  • Completed NCT NCT03868046

    Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)

    Hospital Universitario Araba 242 participants Est. completion 2023-12-31 1 site
    Other conditions: Cancer, Metastatic Cancer, Solid Organ Cancer
    View official trial listing →
  • Terminated NCT NCT03869190

    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

    Not yet reported, Not yet reported Hoffmann-La Roche 272 participants Est. completion 2025-12-22 33 sites Stand-alone
    Other conditions: Urothelial Carcinoma, Bladder Cancer
    View official trial listing →
  • Terminated NCT NCT03892525

    Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

    Not yet reported The Lymphoma Academic Research Organisation 4 participants Est. completion 2021-04-07 5 sites Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03896074

    Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

    Not yet reported Fondazione Ricerca Traslazionale 206 participants Est. completion 2027-05 33 sites Stand-alone
    Other conditions: Non-small-cell Lung Cancer Patients
    View official trial listing →
  • Active, not recruiting NCT NCT03915678

    Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

    Not yet reported Institut Bergonié 247 participants Est. completion 2027-12 11 sites Stand-alone
    Other conditions: Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03961698

    Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

    Not yet reported Infinity Pharmaceuticals, Inc. 91 participants Est. completion 2023-08-31 24 sites Stand-alone
    Other conditions: Breast Cancer, Renal Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT03973879

    Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

    Not yet reported, Not yet reported Darell Bigner Est. completion 2024-01 Stand-alone
    Other conditions: Malignant Glioma
    View official trial listing →
  • Completed NCT NCT03976518

    Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)

    Not yet reported Gruppo Oncologico Italiano di Ricerca Clinica 43 participants Est. completion 2024-02-12 10 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT03979066

    Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

    Not yet reported Gulam Manji 1 participants Est. completion 2019-11-03 1 site Stand-alone
    Other conditions: Pancreatic Ductal Adenocarcinoma
    View official trial listing →
  • Withdrawn NCT NCT03982173

    Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris Est. completion 2024-12-05
    Other conditions: Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma, Esophageal Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT03991403

    Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

    Not yet reported Samsung Medical Center 228 participants Est. completion 2024-03-11 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT04020094

    Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

    Not yet reported University of Utah Est. completion 2021-04-09 1 site Stand-alone
    Other conditions: Prostate Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT04029181

    ImmunoPET With an Anti-CD8 Imaging Agent

    Not yet reported, Not yet reported University Medical Center Groningen 47 participants Est. completion 2024-12 1 site
    Other conditions: Metastatic Cancer, Unresectable Malignant Neoplasm
    View official trial listing →
  • Completed NCT NCT04042558

    A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

    Not yet reported Centre Francois Baclesse 150 participants Est. completion 2025-04-09 31 sites Stand-alone
    Other conditions: NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation
    View official trial listing →
  • Terminated NCT NCT04081688

    Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

    Not yet reported Rutgers, The State University of New Jersey 16 participants Est. completion 2024-04-30 1 site Stand-alone
    Other conditions: Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04082897

    ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

    Not yet reported Niguarda Hospital 28 participants Est. completion 2026-12 17 sites Stand-alone
    Other conditions: CLL Transformation
    View official trial listing →
  • Completed NCT NCT04091217

    Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

    Not yet reported Hoffmann-La Roche 43 participants Est. completion 2023-09-01 3 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT04096638

    Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

    Not yet reported invoX Pharma Limited 61 participants Est. completion 2024-07-16 2 sites Stand-alone
    Other conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
    View official trial listing →
  • Terminated NCT NCT04099836

    Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

    Not yet reported Duke University 7 participants Est. completion 2023-06-15 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04108481

    Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

    Not yet reported University of Iowa 5 participants Est. completion 2023-11-17 1 site
    Other conditions: Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
    View official trial listing →
  • Completed NCT NCT04109456

    IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

    Not yet reported InxMed (Shanghai) Co., Ltd. 51 participants Est. completion 2024-12-20 8 sites Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Completed NCT NCT04123470

    A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

    Not yet reported, Not yet reported Lokon Pharma AB 24 participants Est. completion 2023-07-30 3 sites Stand-alone
    Other conditions: Malignant Melanoma
    View official trial listing →
  • Status unknown NCT NCT04134000

    Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

    Not yet reported Fundacion Oncosur 40 participants Est. completion 2024-09 1 site Stand-alone
    Other conditions: Invasive Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT04136470

    BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

    Ardigen 130 participants Est. completion 2021-03-31 10 sites
    Other conditions: Non Small Cell Lung Cancer, Microbiome, Metagenome, Immunotherapy, Melanoma
    View official trial listing →
  • Completed NCT NCT04148911

    A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 184 participants Est. completion 2024-12-15 67 sites Stand-alone
    Other conditions: Triple-Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT04157985

    Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

    Not yet reported Dan Zandberg 161 participants Est. completion 2025-11-07 1 site
    Other conditions: Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
    View official trial listing →
  • Terminated NCT NCT04167137

    Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

    Not yet reported Synlogic 32 participants Est. completion 2021-12-09 6 sites Stand-alone
    Other conditions: Metastatic Solid Neoplasm, Lymphoma
    View official trial listing →
  • Completed NCT NCT04170556

    Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)

    Not yet reported, Not yet reported Fundacion Clinic per a la Recerca Biomédica 69 participants Est. completion 2024-07-09 7 sites
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT04177108

    A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 242 participants Est. completion 2023-02-28 182 sites Stand-alone
    Other conditions: Triple-Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04180072

    Atezolizumab Plus Bevacizumab With HCC and HBV Infection

    Not yet reported National Health Research Institutes, Taiwan 51 participants Est. completion 2026-12-31 7 sites Stand-alone
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Status unknown NCT NCT04185831

    A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

    Not yet reported Uppsala University Hospital 167 participants Est. completion 2024-10 3 sites Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT04185883

    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Not yet reported Amgen 610 participants Est. completion 2027-12-05 90 sites Stand-alone
    Other conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
    View official trial listing →
  • Active, not recruiting NCT NCT04186013

    Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

    Not yet reported Spanish Oncology Genito-Urinary Group 39 participants Est. completion 2027-05 10 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Completed NCT NCT04194203

    A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

    Not yet reported Hoffmann-La Roche 305 participants Est. completion 2024-06-27 23 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Active, not recruiting NCT NCT04214262

    Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 415 participants Est. completion 2027-06-09 391 sites Stand-alone
    Other conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
    View official trial listing →
  • Terminated NCT NCT04214418

    Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

    Not yet reported, Not yet reported Columbia University 27 participants Est. completion 2022-07-01 2 sites Stand-alone
    Other conditions: Gastrointestinal Cancer
    View official trial listing →
  • Completed NCT NCT04216953

    MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

    Not yet reported, Not yet reported Centre Leon Berard 229 participants Est. completion 2025-03-17 6 sites Stand-alone
    Other conditions: Sarcoma,Soft Tissue
    View official trial listing →
  • Terminated NCT NCT04220775

    Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2022-10-03 1 site
    Other conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
    View official trial listing →
  • Completed NCT NCT04221529

    Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

    Not yet reported AIO-Studien-gGmbH 70 participants Est. completion 2025-04-11 19 sites Stand-alone
    Other conditions: SCLC, Extensive Stage
    View official trial listing →
  • Terminated NCT NCT04222426

    89Zr-atezolizumab PET Scan and Lobular Breast Cancer

    Not yet reported University Medical Center Groningen 1 participants Est. completion 2022-05-01 1 site Stand-alone
    Other conditions: Lobular Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04224636

    Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

    Not yet reported Ludwig-Maximilians - University of Munich 106 participants Est. completion 2025-03-01 7 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma Non-resectable
    View official trial listing →
  • Completed NCT NCT04245085

    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

    Not yet reported ETOP IBCSG Partners Foundation 95 participants Est. completion 2024-07-22 18 sites
    Other conditions: EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
    View official trial listing →
  • Withdrawn NCT NCT04249167

    Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

    Not yet reported Mayo Clinic Est. completion 2021-11-17 Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04262154

    Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 28 participants Est. completion 2026-09 8 sites Stand-alone
    Other conditions: Metastatic Prostate Cancer
    View official trial listing →
  • Withdrawn NCT NCT04267237

    A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

    Not yet reported Hoffmann-La Roche Est. completion 2025-09-30 Stand-alone
    Other conditions: Non-small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Terminated NCT NCT04276376

    Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 130 participants Est. completion 2023-12-12 1 site Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT04289779

    Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

    Not yet reported Deepak Kilari 46 participants Est. completion 2025-12 6 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Completed NCT NCT04294810

    A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

    Not yet reported Hoffmann-La Roche 620 participants Est. completion 2025-12-30 134 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04310020

    Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

    Not yet reported National Cancer Institute (NCI) 47 participants Est. completion 2027-06-01 170 sites Stand-alone
    Other conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04321330

    A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

    Not yet reported Hoffmann-La Roche 34 participants Est. completion 2024-06-03 10 sites Stand-alone
    Other conditions: Carcinoma, Thymic
    View official trial listing →
  • Terminated NCT NCT04322643

    Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

    Not yet reported Case Comprehensive Cancer Center 4 participants Est. completion 2023-04-17 1 site Stand-alone
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04334941

    Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

    Not yet reported National Cancer Institute (NCI) 103 participants Est. completion 2027-01-21 561 sites Stand-alone
    Other conditions: Extensive Stage Lung Small Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT04338269

    A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

    Not yet reported Hoffmann-La Roche 522 participants Est. completion 2025-03-24 135 sites Stand-alone
    Other conditions: Carcinoma, Renal Cell
    View official trial listing →
  • Status unknown NCT NCT04355806

    Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

    Shanghai Pulmonary Hospital, Shanghai, China 160 participants Est. completion 2023-05-31 2 sites
    Other conditions: Non Small Cell Lung Cancer, Influenza Vaccine
    View official trial listing →
  • Active, not recruiting NCT NCT04356729

    A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

    Not yet reported F. Stephen Hodi, MD 30 participants Est. completion 2028-06-01 3 sites Stand-alone
    Other conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
    View official trial listing →
  • Terminated NCT NCT04396535

    Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

    Not yet reported Mayo Clinic 10 participants Est. completion 2023-12-31 3 sites
    Other conditions: Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04400474

    Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

    Not yet reported Grupo Espanol de Tumores Neuroendocrinos 93 participants Est. completion 2023-12-15 15 sites Stand-alone
    Other conditions: Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
    View official trial listing →
  • Suspended NCT NCT04402788

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

    Not yet reported, Not yet reported National Cancer Institute (NCI) 138 participants Est. completion 2027-04-30 411 sites Stand-alone
    Other conditions: Extensive Stage Lung Small Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT04404140

    A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

    Not yet reported Hoffmann-La Roche 6 participants Est. completion 2022-10-14 9 sites Stand-alone
    Other conditions: Castration-Resistant Prostatic Cancer
    View official trial listing →
  • Completed NCT NCT04408118

    First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

    Not yet reported MedSIR 100 participants Est. completion 2023-12-07 26 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04422210

    A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

    Not yet reported Hoffmann-La Roche 2 participants Est. completion 2020-11-06 5 sites Stand-alone
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04442126

    A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported Numab Therapeutics AG 52 participants Est. completion 2024-02-06 26 sites
    Other conditions: Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04449874

    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

    Not yet reported Genentech, Inc. 498 participants Est. completion 2027-12-31 63 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
    View official trial listing →
  • Status unknown NCT NCT04465942

    Immunotherapy in Lung Cancer: Treatment After IO Cessation.

    European Lung Cancer Working Party 300 participants Est. completion 2025-06 5 sites
    Other conditions: Carcinoma, Non-Small-Cell Lung, Immunotherapy
    View official trial listing →
  • Terminated NCT NCT04471415

    Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

    Not yet reported, Not yet reported Dracen Pharmaceuticals, Inc. 61 participants Est. completion 2023-03-28 22 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT04471428

    Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

    Not yet reported Hoffmann-La Roche 366 participants Est. completion 2025-01-17 92 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Active, not recruiting NCT NCT04471727

    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

    Not yet reported, Not yet reported Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232 participants Est. completion 2028-01-28 11 sites Stand-alone
    Other conditions: Small-Cell Lung Cancer, Neuroendocrine Carcinoma
    View official trial listing →
  • Completed NCT NCT04477759

    Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer

    Not yet reported Medical College of Wisconsin 18 participants Est. completion 2025-04-14 1 site Stand-alone
    Other conditions: Head and Neck Neoplasm
    View official trial listing →
  • Completed NCT NCT04487067

    A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

    Not yet reported Hoffmann-La Roche 152 participants Est. completion 2024-08-13 21 sites Stand-alone
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Completed NCT NCT04487756

    Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

    Not yet reported, Not yet reported Instituto Oncológico Dr Rosell 20 participants Est. completion 2025-09-08 3 sites Stand-alone
    Other conditions: Extensive-stage Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04501497

    Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

    Chugai Pharmaceutical 1221 participants Est. completion 2023-02-03 148 sites
    Other conditions: Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT04510584

    Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

    Not yet reported University Health Network, Toronto Est. completion 2023-02-22 1 site Stand-alone
    Other conditions: Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer, TP53 Mutation
    View official trial listing →
  • Active, not recruiting NCT NCT04524871

    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

    Not yet reported, Not yet reported Hoffmann-La Roche 518 participants Est. completion 2027-09-30 32 sites Stand-alone
    Other conditions: Advanced Liver Cancers
    View official trial listing →
  • Completed NCT NCT04540211

    A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

    Not yet reported Hoffmann-La Roche 461 participants Est. completion 2025-08-28 67 sites Stand-alone
    Other conditions: Esophageal Cancer
    View official trial listing →
  • Terminated NCT NCT04541173

    Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

    Not yet reported Aiwu Ruth He, MD 6 participants Est. completion 2023-06-30 6 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04560972

    LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

    Not yet reported City of Hope Medical Center 3 participants Est. completion 2027-01-27 1 site Stand-alone
    Other conditions: Extensive Stage Lung Small Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT04584112

    A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

    Not yet reported Hoffmann-La Roche 83 participants Est. completion 2023-03-08 24 sites Stand-alone
    Other conditions: Triple-Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04589845

    Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

    Not yet reported Hoffmann-La Roche 920 participants Est. completion 2032-09-25 112 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT04602078

    Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

    Not yet reported Spanish Oncology Genito-Urinary Group 82 participants Est. completion 2024-02-02 12 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic Urothelial Carcinoma
    View official trial listing →
  • Terminated NCT NCT04604132

    Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

    Not yet reported, Not yet reported Basilea Pharmaceutica 47 participants Est. completion 2022-11-21 81 sites
    Other conditions: Gastric Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04630730

    Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

    Not yet reported Swiss Cancer Institute 46 participants Est. completion 2030-06 10 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT04631731

    Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

    Not yet reported, Not yet reported Western Sydney Local Health District 200 participants Est. completion 2025-12-10 2 sites
    Other conditions: Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer, Hepatocellular Carcinoma, Endometrial Cancer, Mesothelioma
    View official trial listing →
  • Completed NCT NCT04636762

    A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

    Not yet reported Second Xiangya Hospital of Central South University 40 participants Est. completion 2022-05-01 2 sites Stand-alone
    Other conditions: Extensive-stage Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04639245

    Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 1 participants Est. completion 2022-08-16 1 site Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04639284

    Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

    Shanghai Zhongshan Hospital 200 participants Est. completion 2023-07-31 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04659382

    Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

    Not yet reported Federation Francophone de Cancerologie Digestive 52 participants Est. completion 2024-10-31 19 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy
    View official trial listing →
  • Active, not recruiting NCT NCT04660344

    A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

    Not yet reported Hoffmann-La Roche 761 participants Est. completion 2026-10-01 141 sites Stand-alone
    Other conditions: Muscle-invasive Bladder Cancer
    View official trial listing →
  • Completed NCT NCT04661150

    A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

    Not yet reported Hoffmann-La Roche 42 participants Est. completion 2026-07-27 8 sites Stand-alone
    Other conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT04663438

    Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

    Peking Union Medical College Hospital 300 participants Est. completion 2021-05-30 1 site
    Other conditions: Extensive-stage Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04665856

    Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

    Not yet reported Hoffmann-La Roche 123 participants Est. completion 2025-11-17 16 sites Stand-alone
    Other conditions: Small Cell Lung Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04680598

    Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

    Sun Yat-sen University 800 participants Est. completion 2023-12-31 4 sites
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04708067

    Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

    Not yet reported M.D. Anderson Cancer Center 2 participants Est. completion 2027-02-02 1 site
    Other conditions: Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04721132

    Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

    Not yet reported M.D. Anderson Cancer Center 16 participants Est. completion 2027-12-31 2 sites Stand-alone
    Other conditions: Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04722575

    Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

    Not yet reported Fondazione Melanoma Onlus 95 participants Est. completion 2027-06 6 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT04727307

    Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

    Not yet reported University Hospital, Montpellier 202 participants Est. completion 2031-02 19 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04729959

    Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

    Not yet reported National Cancer Institute (NCI) 61 participants Est. completion 2027-08-20 110 sites Stand-alone
    Other conditions: Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
    View official trial listing →
  • Completed NCT NCT04732598

    A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

    Not yet reported Japanese Foundation for Cancer Research 281 participants Est. completion 2026-03-13 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04739202

    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

    Not yet reported Hospices Civils de Lyon 54 participants Est. completion 2026-06-04 8 sites Stand-alone
    Other conditions: Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma
    View official trial listing →
  • Completed NCT NCT04751929

    Abemaciclib With or Without Atezolizumab for mCRPC

    Not yet reported Dana-Farber Cancer Institute 19 participants Est. completion 2025-11-06 1 site Stand-alone
    Other conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04759248

    Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 55 participants Est. completion 2027-07-01 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04770896

    A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

    Not yet reported Hoffmann-La Roche 557 participants Est. completion 2026-10-14 124 sites Stand-alone
    Other conditions: Unresectable Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT04776447

    Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

    Not yet reported Fundación GECP 38 participants Est. completion 2025-07-31 22 sites Stand-alone
    Other conditions: Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Carcinoma Bronchiogenic Stage III, Thoracic Neoplasms
    View official trial listing →
  • Terminated NCT NCT04801966

    Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

    Not yet reported Peter MacCallum Cancer Centre, Australia 3 participants Est. completion 2022-12-30 1 site Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04808245

    A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

    Not yet reported German Cancer Research Center 15 participants Est. completion 2026-11 8 sites Stand-alone
    Other conditions: Newly Diagnosed H3-mutated Glioma
    View official trial listing →
  • Terminated NCT NCT04832854

    A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

    Not yet reported Hoffmann-La Roche 50 participants Est. completion 2025-03-05 21 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Completed NCT NCT04862949

    Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

    CHA University 131 participants Est. completion 2023-03-09 1 site
    Other conditions: Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04873362

    A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

    Not yet reported Hoffmann-La Roche 1188 participants Est. completion 2034-10-02 238 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04898751

    Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

    Johns Hopkins University 2214 participants Est. completion 2020-08-31 1 site
    Other conditions: Cutaneous Toxicity From ICI Therapy
    View official trial listing →
  • Terminated NCT NCT04902040

    Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 19 participants Est. completion 2025-02-27 1 site Stand-alone
    Other conditions: Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
    View official trial listing →
  • Terminated NCT NCT04923776

    Liver Directed RT + Chemo-immunotherapy for ES-SCLC

    Not yet reported Brian Henick, MD 2 participants Est. completion 2023-12-23 1 site Stand-alone
    Other conditions: Small-cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04924374

    Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

    Not yet reported Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal 25 participants Est. completion 2023-11-15 1 site
    Other conditions: Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04931342

    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not yet reported Hoffmann-La Roche 176 participants Est. completion 2028-05-30 41 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04941287

    Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

    Not yet reported National Cancer Institute (NCI) 57 participants Est. completion 2026-04-29 29 sites Stand-alone
    Other conditions: Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
    View official trial listing →
  • Completed NCT NCT04954339

    DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

    Not yet reported Tae Won Kim 40 participants Est. completion 2026-05-26 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT04971187

    Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

    Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2022-02-21 1 site
    Other conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT04984811

    NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

    Not yet reported NeoImmuneTech 33 participants Est. completion 2024-09-19 22 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT04989283

    Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) Est. completion 2031-05-10 46 sites Stand-alone
    Other conditions: Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04992715

    PD-L1 Expression in Lung Cancer

    Not yet reported NanoMab Technology (UK) Limited 15 participants Est. completion 2023-09 1 site
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT05007613

    Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    Not yet reported National Taiwan University Hospital 24 participants Est. completion 2024-12-01 1 site Stand-alone
    Other conditions: Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT05018273

    Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

    Not yet reported Nykode Therapeutics ASA 26 participants Est. completion 2024-10-09 12 sites Stand-alone
    Other conditions: Solid Tumors, Adult
    View official trial listing →
  • Status unknown NCT NCT05022927

    A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

    Not yet reported Chugai Pharmaceutical 179 participants Est. completion 2025-12-31 11 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Terminated NCT NCT05025514

    Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.

    Centre Hospitalier Universitaire de Nīmes 125 participants Est. completion 2022-09-16 5 sites
    Other conditions: Cancer, Immunotherapy
    View official trial listing →
  • Status unknown NCT NCT05034055

    Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

    Not yet reported Yonsei University 45 participants Est. completion 2023-12 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT05038657

    Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

    Not yet reported University Hospital Southampton NHS Foundation Trust 36 participants Est. completion 2025-01 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma, Urinary Tract Cancer
    View official trial listing →
  • Completed NCT NCT05053737

    Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

    Not yet reported University of Colorado, Denver 11 participants Est. completion 2024-06-21 4 sites Stand-alone
    Other conditions: Squamous Cell Carcinoma of Head and Neck
    View official trial listing →
  • Completed NCT NCT05055947

    Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

    Hunan Province Tumor Hospital 60 participants Est. completion 2021-09-14 1 site
    Other conditions: Extensive Stage Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT05055999

    Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

    Hunan Province Tumor Hospital 60 participants Est. completion 2021-09-01 1 site
    Other conditions: Extensive Stage Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05063552

    Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

    Not yet reported, Not yet reported National Cancer Institute (NCI) 430 participants Est. completion 2027-12-15 172 sites Stand-alone
    Other conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05091567

    A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

    Not yet reported Hoffmann-La Roche 660 participants Est. completion 2028-02-28 93 sites Stand-alone
    Other conditions: Small-Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05097911

    Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

    Not yet reported National University Hospital, Singapore 33 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT05116202

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

    Not yet reported, Not yet reported Hoffmann-La Roche 110 participants Est. completion 2024-05-28 14 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT05118724

    Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

    Not yet reported AIO-Studien-gGmbH 80 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05141721

    A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

    Not yet reported, Not yet reported Seattle Project Corporation 700 participants Est. completion 2027-03 43 sites Stand-alone
    Other conditions: Colorectal Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT05142696

    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

    Not yet reported, Not yet reported Novartis Pharmaceuticals 55 participants Est. completion 2028-03-07 27 sites Stand-alone
    Other conditions: Extensive Stage Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT05171777

    A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

    Not yet reported Hoffmann-La Roche 179 participants Est. completion 2024-10-25 36 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT05197504

    Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

    CHA University 166 participants Est. completion 2023-12-31 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT05199285

    A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

    Not yet reported Academic and Community Cancer Research United 15 participants Est. completion 2026-02-01 5 sites
    Other conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05222932

    Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

    Not yet reported TILT Biotherapeutics Ltd. 15 participants Est. completion 2026-12 2 sites
    Other conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05224141

    Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

    Not yet reported Merck Sharp & Dohme LLC 460 participants Est. completion 2027-06-07 140 sites
    Other conditions: Small Cell Lung Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT05238831

    SMMART Adaptive Clinical Treatment (ACT) Trial

    Not yet reported OHSU Knight Cancer Institute Est. completion 2026-05-31 Stand-alone
    Other conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT05259319

    Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

    Not yet reported Centre Georges Francois Leclerc 92 participants Est. completion 2024-12-05 1 site Stand-alone
    Other conditions: Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT05276284

    Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

    Not yet reported, Not yet reported Kristoffer Rohrberg 18 participants Est. completion 2025-09-01 1 site Stand-alone
    Other conditions: Solid Tumor, Adult, Metastatic Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05286801

    Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

    Not yet reported, Not yet reported National Cancer Institute (NCI) 86 participants Est. completion 2030-03-31 40 sites Stand-alone
    Other conditions: Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
    View official trial listing →
  • Status unknown NCT NCT05295212

    Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

    Not yet reported Hunan Province Tumor Hospital 120 participants Est. completion 2025-07-01 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT05315713

    An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Hoffmann-La Roche 8 participants Est. completion 2023-07-19 17 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05325684

    PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

    Not yet reported, Not yet reported The Affiliated Hospital of Qingdao University 30 participants Est. completion 2023-12 Stand-alone
    Other conditions: Efficacy, Safety
    View official trial listing →
  • Completed NCT NCT05332821

    TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

    Zhongda Hospital 1244 participants Est. completion 2024-01-10 2 sites
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05334329

    Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

    Not yet reported University of California, Irvine 6 participants Est. completion 2027-06-14 1 site Stand-alone
    Other conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05340309

    Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

    Not yet reported University of Southern California 5 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
    View official trial listing →
  • Terminated NCT NCT05359861

    Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

    Not yet reported Coherus Oncology, Inc. 30 participants Est. completion 2025-07-08 37 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05361395

    First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    Not yet reported Amgen 184 participants Est. completion 2030-05-30 44 sites Stand-alone
    Other conditions: Extensive Stage Small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT05396937

    Efficacy and Safety of T+A+RAD in HCC

    Not yet reported Fudan University 42 participants Est. completion 2023-12 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT05411133

    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

    Not yet reported Arbele Pty Ltd 33 participants Est. completion 2025-07-23 3 sites Stand-alone
    Other conditions: Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer, Colorectal Adenocarcinoma, Pancreatic Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Gastroesophageal Junction, Gastrointestinal Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT05448677

    Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

    Not yet reported University Hospital, Grenoble 3 participants Est. completion 2024-03-08 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT05456165

    Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

    Not yet reported Gritstone bio, Inc. Est. completion 2022-09-01 3 sites Stand-alone
    Other conditions: Colonic Neoplasms, Colorectal Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT05468489

    To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

    Not yet reported Shanghai Henlius Biotech 200 participants Est. completion 2027-12-31 67 sites
    Other conditions: Extensive Stage Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05498896

    Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

    Not yet reported Queen Mary University of London 146 participants Est. completion 2026-08-31 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05525858

    KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

    Seoul National University Bundang Hospital 1000 participants Est. completion 2027-03-31 32 sites
    Other conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
    View official trial listing →
  • Terminated NCT NCT05537402

    LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

    Not yet reported University of Texas Southwestern Medical Center 1 participants Est. completion 2025-06-06 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05546879

    Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

    Not yet reported University Hospital, Grenoble 43 participants Est. completion 2029-03-19 9 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05595460

    Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

    Not yet reported RayzeBio, Inc. 21 participants Est. completion 2027-07 13 sites Stand-alone
    Other conditions: SCLC,Extensive Stage
    View official trial listing →
  • Completed NCT NCT05609903

    Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

    Fondazione Policlinico Universitario Agostino Gemelli IRCCS 52 participants Est. completion 2022-05-31 1 site
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT05625893

    Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

    Not yet reported Samsung Medical Center 63 participants Est. completion 2026-03-30 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma, Portal Vein Thrombosis
    View official trial listing →
  • Status unknown NCT NCT05655663

    Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer

    Not yet reported Centre Henri Becquerel 30 participants Est. completion 2025-12-20 2 sites
    Other conditions: Head and Neck Cancer, Lung Cancer
    View official trial listing →
  • Completed NCT NCT05661578

    A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

    Not yet reported Hoffmann-La Roche 64 participants Est. completion 2025-12-26 32 sites Stand-alone
    Other conditions: PD-L1-selected Solid Tumors
    View official trial listing →
  • Completed NCT NCT05665348

    Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

    Not yet reported, Not yet reported Federation Francophone de Cancerologie Digestive 229 participants Est. completion 2025-05-12 45 sites Stand-alone
    Other conditions: HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT05689671

    Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

    Not yet reported Nikolaj Frost MD 136 participants Est. completion 2026-10 36 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer Metastatic
    View official trial listing →
  • Terminated NCT NCT05694013

    Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

    Not yet reported, Not yet reported Hoffmann-La Roche 49 participants Est. completion 2024-06-30 14 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT05703997

    FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 20 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Small Cell Lung Carcinoma
    View official trial listing →
  • Terminated NCT NCT05717400

    Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

    Not yet reported M.D. Anderson Cancer Center 2 participants Est. completion 2024-08-29 1 site Stand-alone
    Other conditions: Liver Cancer
    View official trial listing →
  • Terminated NCT NCT05733611

    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

    Not yet reported Replimune, Inc. 5 participants Est. completion 2025-08-18 2 sites Stand-alone
    Other conditions: Refractory Metastatic Colorectal Cancer, pMMR, MSS
    View official trial listing →
  • Withdrawn NCT NCT05774886

    Implantable Microdevice for TNBC - Pilot Study

    Not yet reported Dana-Farber Cancer Institute Est. completion 2028-09-01 Stand-alone
    Other conditions: Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer, Early Stage Triple-Negative Breast Carcinoma, Breast Neoplasms, Breast Carcinoma
    View official trial listing →
  • Terminated NCT NCT05776875

    Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

    Not yet reported Yale University 3 participants Est. completion 2024-12-05 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05781308

    Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

    Not yet reported Intergroupe Francophone de Cancerologie Thoracique 156 participants Est. completion 2026-06 44 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT05833126

    Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

    Not yet reported Shuhong Yi 25 participants Est. completion 2025-04-01 1 site Stand-alone
    Other conditions: Recurrent Liver Cancer After Liver Transplantation
    View official trial listing →
  • Completed NCT NCT05834348

    A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    Pfizer 5279 participants Est. completion 2024-01-23 1 site
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05836584

    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2027-06-28 133 sites Stand-alone
    Other conditions: Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT05859217

    A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

    Not yet reported Jun Zhang, MD, PhD 40 participants Est. completion 2028-06 4 sites Stand-alone
    Other conditions: Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
    View official trial listing →
  • Completed NCT NCT05867121

    A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

    Not yet reported Genentech, Inc. 102 participants Est. completion 2026-03-16 27 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
    View official trial listing →
  • Withdrawn NCT NCT05886257

    Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

    Not yet reported Shi Ming Est. completion 2023-03-31 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT05886465

    HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

    Not yet reported Sun Yat-sen University 40 participants Est. completion 2024-12-01 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05904886

    A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

    Not yet reported Hoffmann-La Roche 687 participants Est. completion 2026-09-01 171 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT05908786

    A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

    Not yet reported, Not yet reported Hoffmann-La Roche 62 participants Est. completion 2025-11-13 14 sites Stand-alone
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Withdrawn NCT NCT05935774

    OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

    Not yet reported University of Washington Est. completion 2028-07-31 1 site Stand-alone
    Other conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05968326

    A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

    Not yet reported Genentech, Inc. 260 participants Est. completion 2031-01-01 87 sites Stand-alone
    Other conditions: Adenocarcinoma, Pancreatic Ductal
    View official trial listing →
  • Active, not recruiting NCT NCT05999812

    Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

    Not yet reported University of Texas Southwestern Medical Center 22 participants Est. completion 2028-10-01 1 site Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Withdrawn NCT NCT06006286

    A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center Est. completion 2023-11-10 1 site Stand-alone
    Other conditions: Metastatic Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT06024252

    Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study

    Zhongda Hospital 200 participants Est. completion 2024-06-01
    Other conditions: HCC
    View official trial listing →
  • Status unknown NCT NCT06031597

    Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

    Not yet reported Zhejiang Cancer Hospital 105 participants Est. completion 2025-12-31
    Other conditions: Non-small Cell Lung Cancer Stage III
    View official trial listing →
  • Completed NCT NCT06049966

    Atezolizumab in Large Cell Neuroendocrine Carcinoma

    Not yet reported Oncology Center of Biochemical Education And Research 22 participants Est. completion 2025-09-01 3 sites Stand-alone
    Other conditions: Large Cell Neuroendocrine Carcinoma of the Lung
    View official trial listing →
  • Terminated NCT NCT06067061

    "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

    Not yet reported, Not yet reported Institut Curie 2 participants Est. completion 2025-05-07 1 site Stand-alone
    Other conditions: Triple Negative Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT06077500

    DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

    Not yet reported Boehringer Ingelheim 46 participants Est. completion 2027-04-01 21 sites Stand-alone
    Other conditions: Small Cell Lung Carcinoma (SCLC)
    View official trial listing →
  • Withdrawn NCT NCT06090318

    Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

    Not yet reported, Not yet reported Rain Oncology Inc Est. completion 2023-05-30 Stand-alone
    Other conditions: Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06096779

    A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

    Not yet reported Genentech, Inc. 30 participants Est. completion 2027-12-30 59 sites Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT06099418

    Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

    Not yet reported Nykode Therapeutics ASA Est. completion 2028-05 Stand-alone
    Other conditions: HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06138769

    Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

    Not yet reported Asan Medical Center 50 participants Est. completion 2027-11-01 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT06169904

    B7-Family Score in Urothelial Carcinoma

    Shanghai Zhongshan Hospital 215 participants Est. completion 2022-11-22
    Other conditions: Urothelial Carcinoma
    View official trial listing →
  • Status unknown NCT NCT06195683

    Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

    Not yet reported Zhejiang Cancer Hospital 23 participants Est. completion 2025-06-20 1 site
    Other conditions: Non-small Cell Lung Cancer, PDL1 Gene Mutation
    View official trial listing →
  • Completed NCT NCT06199297

    Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

    Sun Yat-sen University 188 participants Est. completion 2023-07-25 1 site
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT06205732

    A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

    Qianfoshan Hospital 100 participants Est. completion 2024-12 1 site
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Status unknown NCT NCT06244446

    Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.

    Institute of Liver and Biliary Sciences, India 40 participants Est. completion 2025-01-31 1 site
    Other conditions: Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT06267001

    A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

    Not yet reported Hoffmann-La Roche 56 participants Est. completion 2025-12-16 37 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Withdrawn NCT NCT06331598

    A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

    Not yet reported Hoffmann-La Roche Est. completion 2029-09-20 3 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT06416683

    Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)

    University Hospital, Caen 109 participants Est. completion 2024-01-30 1 site
    Other conditions: Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT06488716

    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

    Not yet reported Genentech, Inc. 12 participants Est. completion 2025-11-05 11 sites Stand-alone
    Other conditions: Solid Tumour
    View official trial listing →
  • Active, not recruiting NCT NCT06496568

    A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

    Not yet reported Hoffmann-La Roche 30 participants Est. completion 2027-07-21 5 sites Stand-alone
    Other conditions: PIK3CA-Mutated Cancers
    View official trial listing →
  • Active, not recruiting NCT NCT06537310

    A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

    Not yet reported Hoffmann-La Roche 34 participants Est. completion 2027-08-10 11 sites Stand-alone
    Other conditions: Cancer-Neoplasms
    View official trial listing →
  • Not yet recruiting NCT NCT06584071

    A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

    Not yet reported, Not yet reported Biotheus Inc. 140 participants Est. completion 2027-12
    Other conditions: HCC, Liver Cancer
    View official trial listing →
  • Withdrawn NCT NCT06603818

    Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

    Not yet reported National Cancer Institute (NCI) Est. completion 2025-08-15 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Metastatic Colorectal Cancer, Colorectal Cancer
    View official trial listing →
  • Suspended NCT NCT06616623

    Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

    Not yet reported Dwight Owen 24 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT06632327

    Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 37 participants Est. completion 2030-04-30 415 sites Stand-alone
    Other conditions: Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
    View official trial listing →
  • Not yet recruiting NCT NCT06680258

    A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

    Not yet reported Tempest Therapeutics 740 participants Est. completion 2030-07 Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Not yet recruiting NCT NCT06692491

    Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

    Not yet reported Peking University Shenzhen Hospital 200 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Rare Tumour
    View official trial listing →
  • Withdrawn NCT NCT06713798

    Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris Est. completion 2025-09-15 Stand-alone
    Other conditions: Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06719336

    Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

    Not yet reported Anhui Shi, MD 182 participants Est. completion 2028-12-16 Stand-alone
    Other conditions: Extensive-stage Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06754501

    A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2029-07-01 1 site Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06760481

    Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

    Not yet reported M.D. Anderson Cancer Center 7 participants Est. completion 2030-09-15 1 site Stand-alone
    Other conditions: Advanced Solid Malignancies
    View official trial listing →
  • Withdrawn NCT NCT06762808

    Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

    Not yet reported M.D. Anderson Cancer Center Est. completion 2025-08-08 Stand-alone
    Other conditions: Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT06771622

    Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported FBD Biologics Limited 500 participants Est. completion 2029-01-01 1 site Stand-alone
    Other conditions: Solid Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06784947

    Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

    Not yet reported University of Colorado, Denver 13 participants Est. completion 2028-05 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
    View official trial listing →
  • Not yet recruiting NCT NCT06984718

    A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

    Not yet reported Akeso 120 participants Est. completion 2027-06-30
    Other conditions: HCC, Hepatocellular Carcinoma
    View official trial listing →
  • Completed NCT NCT07036016

    Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 67818 participants Est. completion 2025-05-01
    Other conditions: Non-Small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Not yet recruiting NCT NCT07170592

    A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

    Not yet reported Bionoxx Inc. 24 participants Est. completion 2030-12 Stand-alone
    Other conditions: Treatment-Refractory Solid Tumors
    View official trial listing →
  • Not yet recruiting NCT NCT07172412

    Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 165 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Extensive Stage Lung Small Cell Cancer
    View official trial listing →
  • Completed NCT NCT07192926

    Body Composition and Blood-Based Prognostic Markers in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer

    Ankara Etlik City Hospital 155 participants Est. completion 2026-06-11 2 sites
    Other conditions: Metastatic Non-small Cell Lung Cancer, Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT07280377

    A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

    Not yet reported, Not yet reported Oncolytics Biotech 122 participants Est. completion 2028-12-31 15 sites Stand-alone
    Other conditions: Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07281664

    Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

    Not yet reported Third Affiliated Hospital, Sun Yat-Sen University 30 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Hepatocellular Carcinoma, Transarterial Chemoembolization
    View official trial listing →
  • Not yet recruiting NCT NCT07363356

    Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer

    Not yet reported Eastern Hepatobiliary Surgery Hospital 56 participants Est. completion 2028-11-30 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma Resectable
    View official trial listing →
  • Not yet recruiting NCT NCT07461675

    Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

    Not yet reported University of Geneva, Switzerland 30 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Hepato Cellular Carcinoma (HCC), Immunotherapy
    View official trial listing →
  • Enrolling by invitation NCT NCT07620574

    Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

    Not yet reported Exelixis 5000 participants Est. completion 2030-05-31 2 sites Stand-alone
    Other conditions: Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
    View official trial listing →
  • Completed NCT NCT07639294

    The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study

    Tongji Hospital 715 participants Est. completion 2025-12-31 1 site
    Other conditions: Huge Hepatocellular Carcinoma (HCC) (>10cm)
    View official trial listing →
  • Active, not recruiting NCT NCT07645209

    A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions

    Harbin Medical University 1000 participants Est. completion 2029-05-13 1 site
    Other conditions: Liver Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07707895

    DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

    Not yet reported, Not yet reported Boehringer Ingelheim 60 participants Est. completion 2030-04-26 27 sites Stand-alone
    Other conditions: Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
    View official trial listing →
  • Not yet recruiting NCT NCT07734857

    Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

    Shanghai Zhongshan Hospital 100 participants Est. completion 2028-07-30
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Not yet recruiting NCT NCT07770100

    Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

    Not yet reported Mark Bernard 35 participants Est. completion 2040-02-28 1 site Stand-alone
    Other conditions: Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Atezolizumab, TECENTRIQ, MPDL 3280A, MPDL 328OA, RG 7446, RO 5541267

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.